Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalMental HealthDepressionTrial Update

Pilot Trial of Digitally Enhanced Stepped-Care for Depression in Primary Care Initiated

The pilot trial of a digitally enhanced stepped-care approach for depression could redefine treatment paradigms in primary care, particularly in the mental health space. Its success may lead to significant shifts in how depression is managed, impacting both traditional therapy models and digital health competitors.

Published: June 11, 2026
Updated: June 11, 2026
Author: Humanexa Intelligence
Therapeutic area: Mental Health / Depression
Asset: Moodivate
Trial SummaryCLN

Phase III

Mental Health / Depression

Status

Initiated

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The pilot trial of a digitally enhanced stepped-care approach for depression could redefine treatment paradigms in primary care, particularly in the mental health space. Its success may lead to significant shifts in how depression is managed, impacting both traditional therapy models and digital health competitors.

Why it matters

The pilot trial of a digitally enhanced stepped-care approach for depression could redefine treatment paradigms in primary care, particularly in the mental health space. Its success may lead to significant shifts in how depression is managed, impacting both traditional therapy models and digital health competitors.

What changed

Trial Update

Analysis

A pilot trial is evaluating a digitally enhanced stepped-care approach for treating depression in primary care settings.

The pilot trial of a digitally enhanced stepped-care approach for depression could redefine treatment paradigms in primary care, particularly in the mental health space. Its success may lead to significant shifts in how depression is managed, impacting both traditional therapy models and digital health competitors.

Monitor results on feasibility and PHQ-9 score changes, as well as potential scalability of the approach in broader settings.

Related companies & assets

Assets

  • MUSC Primary Care clinics →
  • Moodivate →
  • telebehavioral health providers →
  • digital mental health solutions →

Sources & Humanexa intelligence

Source links

  • Digitally Enhanced Stepped-Care for Depression in Primary Care ↗
  • Pilot Trial of Digitally Enhanced Stepped-Care for Depression in Primary Care Initiated ↗

Related Humanexa pages

  • Pilot Trial of Digitally Enhanced Stepped-Care for Depression in Primary Care Initiated →

Related signals

Trial SummaryCLN

Phase III

gastric cancer therapies

Status

Active

Signal Score

8.4

Clinicalhigh signal

FTO/BCL6 Axis Identified as Therapeutic Target in Gastric Cancer Progression

FTO-mediated demethylation of BCL6 promotes gastric cancer progression by inhibiting ferroptosis.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

epithelial ovarian cancer

Status

Active

Signal Score

8.4

Clinicalhigh signal

Targeted PEGylated PLGA Nanoparticles Enhance Hesperidin Delivery in Ovarian Cancer

Hesperidin-loaded PEGylated PLGA nanoparticles demonstrate improved dissolution and cytotoxicity in EOC models.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.